A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive-controlled, Placebo-controlled, Parallel, Nested-crossover (Moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
Latest Information Update: 07 Apr 2025
At a glance
- Drugs BMS-986419 (Primary) ; Moxifloxacin
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 01 Apr 2025 Status changed from not yet recruiting to recruiting.
- 05 Mar 2025 New trial record